$LLY said its oral GLP-1 orforglipron beat oral semaglutide in a 52-week head-to-head diabetes trial (The Lancet). A1C fell 2.2% w/ orforglipron 36mg vs 1.4% with semaglutide 14mg, and weight loss was 19.7lbs (9.2%) vs 11lbs (5.3%). Discontinuations were higher with orforglipron.